Danaher Corporation (DHR): what the price assumes

In the published model solve dated 2026-Q2, anchored at $216.07, Danaher Corporation (DHR) is priced for +24.0% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/DHR

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.1% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.9%); the inversion above states its own rate.

Per-Model Detail (n=17)

Economic-Unit Decomposition (Sum Of The Parts)

The disclosed units share an operating capital structure; consolidated cash-flow lenses remain coherent and the unit split is explanatory.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• Consumables, services and other repeat business made up $20.1 billion of $24.6 billion in 2025 revenue and grew from $19.4 billion, while one-time equipment sales shrank.
• Trailing return on equity of 7.0% sits below the roughly nine percent that equity investors require of a business like this, which is the single fact behind why no standard valuation frame reaches today's price.
• A signed agreement to buy Masimo for roughly 9.9 billion dollars, dated February 16, 2026 and partly funded with new borrowing, is the next event that changes the shape of the company.

Bull Case

Follow the capital and the strategy explains itself. In February 2026 the company signed a definitive agreement to acquire Masimo, a patient-monitoring and pulse-oximetry business, for roughly 9.9 billion dollars including assumed borrowings and net of the cash arriving with it. That is the move this management team has run for decades: buy a business with a durable installed base, apply the operating system, and let the supplies that flow through the installed base do the compounding. The purchase is partly financed with new borrowing, and there is ample room for it. Interest expense in the March quarter was 63 million dollars against operating profit of 1.34 billion.

The compounding mechanism deserves stating precisely, because it is what separates this from an equipment manufacturer. The annual filing describes the consumables as typically critical to the use of the equipment and are typically used on a one-time or limited basis, requiring frequent replacement in the customer's operating cycle, naming reagents used in diagnostic tests, chromatography resins used for bioprocessing, and filters. Once a customer validates a particular resin into a drug manufacturing process, switching it means going back to a regulator. In 2025 that repeat business was $20.1 billion of $24.6 billion in revenue, up from $19.4 billion, while one-time equipment revenue slipped to $4.4 billion from $4.5 billion. Equipment sales shrank and the things that run through the equipment grew. For this business model that is the right way round.

Inside Biotechnology the same split is sharper still. Repeat revenue in that segment reached $6.4 billion in 2025 from $5.8 billion, while its equipment line fell to $0.9 billion from $1.0 billion. Customers are running the capacity they already own harder instead of buying more, which is exactly what the early stage of a bioprocessing recovery looks like from the supplier's side. Segment operating profit followed in the March 2026 quarter, rising to $534 million from $441 million.

Profitability is holding while all of that happens. Operating profit margin rose 40 basis points from 22.2% a year earlier in the March quarter, helped by price contributing to sales growth and by better leverage on the cost base. That level compares well within the scaled cohort: TMO runs a 17.5% operating margin on $45.2 billion of revenue and A runs 21.5% on $7.2 billion.

And the share count moves the right way even while the company spends. Diluted shares averaged 711.2 million in the March quarter against 720.8 million a year earlier. A company funding a ten-billion-dollar acquisition and shrinking its own equity base at the same time is telling you it does not believe it has to choose between the two.

The bear's objection is that every bit of this is already in the price, and the next section makes that case properly. The bull's claim is narrower: the compounding engine is intact, and it is currently running on the half of the business that does not wait for a customer's capital budget to be approved.

Bear Case

The uncomfortable observation arrives before any ratio does. Danaher currently earns about seven cents of profit for every dollar of shareholder equity. Investors in a business of this risk require closer to nine. A company earning less on its own book than its owners need is, in the plainest arithmetic, not creating value on that book, and the reason is no mystery: decades of acquisitions have piled goodwill and intangibles onto the balance sheet, and goodwill earns nothing by itself. The operating businesses sitting on top are genuinely excellent. The equity base underneath them is enormous.

That gap is why no standard way of valuing this company reaches today's price. The price sits about four times above where asset-based methods land. It sits about three and a half times above the earnings-power methods, which capitalize what the business earns now and credit no growth. It sits a bit over twice above peer-multiple methods. Even the forward cash-flow methods, the most generous frames available and the only ones that project growth at all, land about a third under the price. When every family sits below, the premium is not a disagreement among methods that one of them will win. It is a bet beyond all of them.

Stated in operating terms, the price needs profit to compound at close to the fastest rate the company can fund from its own cash flow for about five years, and it needs the operating margin to reach roughly 21% against the 19.1% earned on a trailing basis. Neither is absurd on its own. Duration is what makes it a stretch: only about 29% of comparable fast-growers sustained that pace for a comparable stretch. Nor is the assumption robust to small disappointments. Each percentage point of growth surrendered takes roughly two years off the horizon the price requires, which means the distance between a good year and an ordinary one is a large fraction of the entire bet.

The near-term evidence in the largest segment runs the other way. Diagnostics operating profit fell to $674 million from $718 million in the March quarter, with core sales down on weaker demand for respiratory testing, led by North America and China, and with the China decline partly a matter of price rather than volume. Price pressure that comes from how a national buyer procures does not reverse because a cycle turns. A diagnostics franchise selling into a customer that negotiates nationally on price gets its margin back by changing the product mix, not by waiting.

Masimo is the third concern, and it is a departure. Roughly 9.9 billion dollars buys a patient-monitoring business rather than another consumables franchise, and the filing states the funding plainly: The Company expects to incur debt to finance a portion of the purchase price for our pending acquisition of Masimo Corporation. Total borrowings already stood at 18.5 billion dollars at the end of March against 5.7 billion of cash and equivalents. Coverage is not remotely the issue here. The issue is that a company priced for five uninterrupted years of ceiling-rate compounding has chosen to run a large integration through the middle of that window.

None of this makes the business a bad one. It says the price has already paid for the business being very good for a long time, while the recent evidence shows a diagnostics segment shrinking, an equipment line still contracting, and a ten-billion-dollar deal that has to work. What is thin here is the margin for error in the price, not the quality of the company.

Valuation

Today's $191.49 values the operating business at about 33 times its trailing operating income. Invert that at a cost of capital near 8.4% and the assumption becomes explicit: operating profit compounding at close to the fastest rate the company can fund from its own cash flow, held for about five years. The same demand stated the other way is an operating margin reaching roughly 21% against the 19.1% earned on a trailing basis. The price is not asking for a transformation. It is asking for excellence to continue without an interruption.

Every family of method lands under that price, which is a less common result than it sounds. The price sits about four times above where the asset-value methods land, and the mechanism behind that gap is worth naming: book value per share is $74.45 while trailing return on equity runs 7.0%, below what equity investors require, so the book itself does not justify much. Earnings-power methods sit about three and a half times under the price, peer-multiple methods a bit over twice. Even the forward cash-flow methods land about a third under, and the more generous of the two gets as close as it does by holding the exit multiple where it stands today rather than allowing it to fade. When no standard frame reaches the price, the premium is not a dispute among methods. It is the market paying for durability none of them is built to encode.

How demanding is five years at that pace? Only about 29% of comparable fast-growers sustained it for a comparable stretch, and the assumption is sensitive to small misses. Each percentage point of growth surrendered removes roughly two years from the horizon the price requires. That sensitivity, more than the growth rate itself, is what a buyer at this level is actually underwriting.

Against the scaled cohort the operating quality is genuine and the multiple is the open question. TMO earns a 17.5% operating margin on $45.2 billion of revenue and A earns 21.5% on $7.2 billion, while Danaher reported operating profit margin up 40 basis points from 22.2% in the March 2026 quarter. Mix explains much of the difference: repeat business was $20.1 billion of $24.6 billion of 2025 revenue, and supplies carry better economics than the instruments they run through.

The balance sheet neither constrains the story nor rescues it. Total borrowings stood at 18.5 billion dollars at the end of March against 5.7 billion of cash and equivalents, and interest expense of 63 million in the quarter was covered many times over by operating profit of 1.34 billion. Diluted shares averaged 711.2 million against 720.8 million a year earlier, so capital is still returning to holders with a large acquisition pending. There is no solvency question here to put a floor under the downside. The multiple is what bounds it, and the multiple is the entire argument.

Catalysts

Second-quarter results landed on July 21, 2026, and the market did not enjoy them. The company trimmed its revenue outlook while raising its profit forecast, with the shortfall concentrated in biotechnology, and the shares fell sharply on the print. Those two moves in combination describe a company defending margin while volume disappoints. That is the same picture the March quarter painted, and it becomes harder to sustain the longer the volume shortfall runs.

The sell-side response was to cut targets while keeping constructive ratings. Deutsche Bank lowered its target to $240 from $250, BofA to $230 from $270 while calling the overall numbers fine, and Argus held a Buy rating with a $230 target on the view that the selloff created an opportunity. Those levels sit well above the current price and well above where every standard frame in this report lands. The difference is not arithmetic error on either side: the street is crediting a forward earnings recovery that trailing methods are structurally unable to see, and this report is measuring what the price already assumes rather than forecasting the recovery.

The larger item on the calendar is Masimo. The definitive agreement was signed on February 16, 2026 for roughly 9.9 billion dollars including assumed borrowings and net of acquired cash, and the company has said it expects to borrow to fund part of the price. Regulatory review and closing conditions sit between here and completion. Two things are worth watching when it does close: whether the acquired revenue looks like the repeat kind this operating model runs on, and what the financing ends up costing, because a price assuming five uninterrupted years of compounding has no room in it for an integration that goes sideways.

Peer Cohorts (Per Segment, With Filing Citations)

Biotechnology / Life Sciences / Diagnostics (reported)

• TMO (THERMO FISHER SCIENTIFIC INC.)
• FY2025 10-K: …our customers to make the world healthier, cleaner and safer. We serve customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process…
• FY2025 10-K: …clinical, healthcare, academic, and government markets. Life Sciences Solutions includes three primary businesses: biosciences, genetic sciences, and bioproduction. 3 THERMO FISHER SCIENTIFIC INC. Our biosciences business includes reagents, instruments and consumables that help our customers conduct biological and…
• A (AGILENT TECHNOLOGIES, INC.)
• FY2025 10-K: …common goal of patient health and safety. We offer our pharmaceutical customers even more specialized manufacturing capabilities for targeted therapeutics. Together, our BIOVECTRA and nucleic acid solutions businesses provide clinical-to-commercial scale production capabilities. Biomolecular Analysis Automated…
• FY2025 10-K: …modalities. Together, our BIOVECTRA and nucleic acid solutions businesses comprise our specialty CDMO offerings to our customers providing clinical-to-commercial scale production capabilities. Fourth, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology…
• MTD (Mettler-Toledo International Inc.)
• FY2025 10-K: …development and scale-up activities of our customers. Our on-line measurement technologies, based on infrared and laser light scattering, enable customers to monitor chemical reactions and crystallization processes in real time in the lab and plant. In situ samples allow overnight sampling and testing. Additionally,…
• FY2025 10-K: …our innovative portfolio have also allowed us to quickly capitalize on our customers' demand for automation and digitalization solutions and faster growing segments. We are well positioned and have continued to make investments to further strengthen our portfolio and capture future growth opportunities. Our service…
• WAT (Waters Corporation)
• FY2025 10-K: …instruments to life science, pharmaceutical, biochemical, industrial, nutritional safety and environmental, academic and governmental customers working in research and development, quality assurance and other laboratory applications, and the Company is also a developer and supplier of software and software-based…
• FY2025 10-K: …like empty, partial and full viral vector capsids, using up to 100-fold less sample volume than that required by current techniques, and delivering results in less than ten minutes, even at concentrations as low as 1010 vp/mL. This new capability paves the way for real-time characterization of gene therapies during…
• RVTY (REVVITY, INC)
• FY2025 10-K: …talented and engaged employees; • Accelerating transformational innovation through both internal research and development and third-party collaborations and alliances; • Augmenting growth in both of our core business segments, Life Sciences and Diagnostics, through strategic acquisitions and licensing; • Advancing…
• FY2025 10-K: …cell contamination throughout bioprocessing workflows. 8 Table of Contents Brand Names: Our Life Sciences segment offers additional products under various brand names: Accell™, AlphaLISA ® , AlphaPlex ™ , AlphaScreen ® , Alpha™ SureFire ® , AssayMate™, BIOCHIPs™, BioLegend ® , Bioo Scientific ® , BioQule™, Brilliant…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.